delpacibart braxlosiran   Click here for help

GtoPdb Ligand ID: 14729

Synonyms: AOC 1020 | AOC-1020 | del-brax
Compound class: Nucleic acid
Comment: Delpacibart braxlosiran is structurally a monoclonal antibody (mAb)-oligonucleotide conjugate (AOC) in which the mAb binds the transferrin receptor (TFRC;) for targeted delivery of a small interfering RNA (siRNA) payload that targets double homeobox 4 (DUX4) mRNA [1].

This entry provides information on the siRNA as the component that mediates the agent's intended pharmacodynamic effect. Further details about the parental anti-TFRC mAb are provided in the delpacibart entry. To improve pharmacokinetics and RNA binding the nucleotides in braxlosiran (siDUX4.6) are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone. The delpacibart component is attached at the 5' end of the passenger strand via a malemide linker

Aberrant activation of the DUX4 gene in skeletal muscle causes the progressive muscle-wasting disease facioscapulohumeral muscular dystrophy (FSHD). The braxlosiran siRNA is intended to reduce DUX4 expression in skeletal muscle [1].
No information available.
Summary of Clinical Use Click here for help
Delpacibart braxlosiran (AOC-1020) was progressed as a clinical candidate for its potential to treat facioscapulohumeral muscular dystrophy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06547216 Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 2 Interventional Avidity Biosciences, Inc.
NCT07038200 A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD Phase 3 Interventional Avidity Biosciences, Inc.